Literature DB >> 15708928

Psoriasis: epidemiology, clinical features, and quality of life.

R G B Langley1, G G Krueger, C E M Griffiths.   

Abstract

Psoriasis is a common chronic, recurrent, immune mediated disease of the skin and joints. It can have a significant negative impact on the physical, emotional, and, psychosocial wellbeing of affected patients. Psoriasis is found worldwide but the prevalence varies among different ethnic groups. It has a strong genetic component but environmental factors such as infections can play an important role in the presentation of disease. There are several clinical cutaneous manifestations of psoriasis but most commonly the disease presents as chronic, symmetrical, erythematous, scaling papules and plaques. The epidemiology, clinical features, and impact on quality of life of psoriasis are reviewed.

Entities:  

Mesh:

Year:  2005        PMID: 15708928      PMCID: PMC1766861          DOI: 10.1136/ard.2004.033217

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  49 in total

1.  Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci.

Authors:  C D Veal; R L Clough; R C Barber; S Mason; D Tillman; B Ferry; A B Jones; M Ameen; N Balendran; S H Powis; A D Burden; J N Barker; R C Trembath
Journal:  J Med Genet       Date:  2001-01       Impact factor: 6.318

2.  Psoriasis--an index of disability.

Authors:  A Y Finlay; S E Kelly
Journal:  Clin Exp Dermatol       Date:  1987-01       Impact factor: 3.470

3.  Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

Authors:  G G Krueger; S R Feldman; C Camisa; M Duvic; J T Elder; A B Gottlieb; J Koo; J G Krueger; M Lebwohl; N Lowe; A Menter; W L Morison; J H Prystowsky; J L Shupack; J R Taylor; G D Weinstein; T L Barton; T Rolstad; R M Day
Journal:  J Am Acad Dermatol       Date:  2000-08       Impact factor: 11.527

4.  Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden.

Authors:  F Enlund; L Samuelsson; C Enerbäck; A Inerot; J Wahlström; M Yhr; A Torinsson; J Riley; G Swanbeck; T Martinsson
Journal:  Eur J Hum Genet       Date:  1999 Oct-Nov       Impact factor: 4.246

5.  Australian Aborigines and psoriasis.

Authors:  A C Green
Journal:  Australas J Dermatol       Date:  1984-04       Impact factor: 2.875

6.  Mode of inheritance in psoriasis.

Authors:  P R Burch; N R Rowell
Journal:  Arch Dermatol       Date:  1981-05

7.  The Salford Psoriasis Index: an holistic measure of psoriasis severity.

Authors:  B Kirby; D G Fortune; M Bhushan; R J Chalmers; C E Griffiths
Journal:  Br J Dermatol       Date:  2000-04       Impact factor: 9.302

8.  Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13.

Authors:  Y A Lee; F Rüschendorf; C Windemuth; M Schmitt-Egenolf; A Stadelmann; G Nürnberg; M Ständer; T F Wienker; A Reis; H Traupe
Journal:  Am J Hum Genet       Date:  2000-09-13       Impact factor: 11.025

9.  Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris.

Authors:  T Henseler; E Christophers
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

10.  Palmoplantar pustulosis and smoking.

Authors:  C J O'Doherty; C MacIntyre
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-28
View more
  194 in total

1.  Carotid intima-media thickness and epicardial fat thickness predict precoronary artery disease status in psoriasis.

Authors:  Banavasi Shanmukha Girisha; Shajahan Shibina; U Raghuraja; K Subramanyam
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

2.  To what extend is nail ultrasound discriminative between psoriasis, psoriatic arthritis and healthy subjects?

Authors:  Esperanza Naredo; Iustina Janta; Ofelia Baniandrés-Rodríguez; Lara Valor; Michelle Hinojosa; Natalia Bello; Belén Serrano; Jesús Garrido
Journal:  Rheumatol Int       Date:  2018-12-10       Impact factor: 2.631

3.  Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells.

Authors:  Sayaka Shibata; Yayoi Tada; Carren Sy Hau; Aya Mitsui; Masahiro Kamata; Yoshihide Asano; Makoto Sugaya; Takafumi Kadono; Yosuke Masamoto; Mineo Kurokawa; Toshimasa Yamauchi; Naoto Kubota; Takashi Kadowaki; Shinichi Sato
Journal:  Nat Commun       Date:  2015-07-15       Impact factor: 14.919

4.  Ostraceous and inverse psoriasis with psoriatic arthritis as the presenting features of advanced HIV infection.

Authors:  Rochelle Lorenzo Castillo; Geraldine Zamora Racaza; Francisca Dela Cruz Roa
Journal:  Singapore Med J       Date:  2014-04       Impact factor: 1.858

Review 5.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

6.  Genetics of psoriasis and psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

7.  Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.

Authors:  María Denise Takahashi; Edgardo Néstor Chouela; Gladys Leon Dorantes; Ana Maria Roselino; Jesùs Santamaria; Miguel Angel Allevato; Tania Cestari; Maria Eugenia Manzanera de Aillaud; Fernando Miguel Stengel; Daiana Licu
Journal:  Arch Drug Inf       Date:  2010-03

8.  Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial.

Authors:  Torello Lotti; Sergio Chimenti; Andreas Katsambas; Jean-Paul Ortonne; Louis Dubertret; Daiana Licu; Jan Simon
Journal:  Arch Drug Inf       Date:  2010-03

9.  Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets.

Authors:  Bertalan Mesko; Szilard Poliska; Andrea Szegedi; Zoltan Szekanecz; Karoly Palatka; Maria Papp; Laszlo Nagy
Journal:  BMC Med Genomics       Date:  2010-05-05       Impact factor: 3.063

10.  Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.

Authors:  Andreas Katsambas; Ketty Peris; Gino Vena; Peter Freidmann; Gottfried Wozel; Esteban Daudén; Daiana Licu; Mauro Placchi; Michel De La Brassinne
Journal:  Arch Drug Inf       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.